Skip to main navigation Skip to search Skip to main content

New Pathways in Syphilis Vaccine Development

  • Andy Liu
  • , Lorenzo Giacani
  • , Kelly L. Hawley
  • , Caroline E. Cameron
  • , Arlene C. Seña
  • , Kelika A. Konda
  • , Justin D. Radolf
  • , Jeffrey D. Klausner
  • Keck School of Medicine of USC
  • University of Washington
  • School of Public Health
  • Division of Infectious Diseases
  • UConn Health
  • University of Victoria
  • The University of North Carolina at Chapel Hill
  • UConn Health

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The New Pathways in Syphilis Vaccine Development meeting was held before the start of the STI & HIV 2023 World Congress as a pre-meeting symposium to highlight recent advances in the development of an effective syphilis vaccine and discuss the challenges still faced by investigators. Internationally renowned public health officials, clinical investigators, and basic researchers from academia, government, and community-based organizations met on July 24, 2023, in Chicago, Illinois. Four speakers discussed key research findings in syphilis vaccine development, which included antigen selection, identification of epitopes associated with protective immunity, and delivery platforms, with great emphasis on development of chimeric antigens. Significant progress was also shown on the elucidation of Treponema pallidum genomes from virtually all continents to assess the diversity in vaccine candidates of the syphilis spirochete.

Original languageEnglish
Pages (from-to)e49-e53
JournalSexually Transmitted Diseases
Volume51
Issue number11
DOIs
StatePublished - 1 Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'New Pathways in Syphilis Vaccine Development'. Together they form a unique fingerprint.

Cite this